RT Journal Article
SR Electronic
T1 International multicenter examination of MOG antibody assays
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e674
DO 10.1212/NXI.0000000000000674
VO 7
IS 2
A1 Markus Reindl
A1 Kathrin Schanda
A1 Mark Woodhall
A1 Fiona Tea
A1 Sudarshini Ramanathan
A1 Jessica Sagen
A1 James P. Fryer
A1 John Mills
A1 Bianca Teegen
A1 Swantje Mindorf
A1 Nora Ritter
A1 Ulrike Krummrei
A1 Winfried Stöcker
A1 Juliane Eggert
A1 Eoin P. Flanagan
A1 Melanie Ramberger
A1 Harald Hegen
A1 Kevin Rostasy
A1 Thomas Berger
A1 Maria Isabel Leite
A1 Jacqueline Palace
A1 Sarosh R. Irani
A1 Russell C. Dale
A1 Christian Probst
A1 Monika Probst
A1 Fabienne Brilot
A1 Sean J. Pittock
A1 Patrick Waters
YR 2020
UL http://nn.neurology.org/content/7/2/e674.abstract
AB Objective To compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.Methods The following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG).Results We found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.Conclusions Live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.ADEM=acute disseminated encephalomyelitis; AQP4=aquaporin-4; CBA=cell-based assay; FACS=fluorescence-activated cell sorting; IF=immunofluorescence; IfQ=Institute for Quality Assurance; Ig=immunoglobulin; MOG=myelin oligodendrocyte glycoprotein; NMOSD=neuromyelitis optica spectrum disorder